628 Results
Sort By:
Published on December 13, 2022
Adding the immunotherapy blinatumomab after an initial round of consolidation chemotherapy in patients with good prognosis with B lineage acute lymphoblastic leukemia (ALL) kept most patients in remission and improved survival. Results of the randomized Phase III study showed that after three-and-a-half years of follow up, 83% of patients who…
Published on December 12, 2022
A genetic marker can identify patients at high risk of potentially serious side effects from immunotherapy used to treat melanoma skin cancer. Researchers identified the first genetic risk factor for immunotherapy toxicity in the IL-7 gene, which codes for an important factor in lymphocyte survival. Carriers had up to a…
Published on December 7, 2022
In a reversal to accepted theories, scientists have discovered the adding radiation to immunotherapy does not boost the immune system. It’s actually the reverse. Yet, in several cancers, the combination together shows improved treatment responses over either treatment alone. The reason may have more to do with the tumor’s aneuploidy…
Published on December 7, 2022
Cancer patients’ response to immunotherapy may be predictable in part based on their levels of CD8+ T-cell infiltration, according to a new study. Such drugs are one of the world’s highest selling classes, estimated to have netted over $31B in 2021 and expected to bring almost $150M by 2030. But…
Published on November 30, 2022
Researchers from the University of Pittsburgh have developed a new cancer treatment strategy involving co-delivery of a chemotherapy drug and a newly identified immunotherapy. The team’s mission was to find new ways to eliminate residual cancer cells that evade chemotherapy and radiation. “We took a dual approach to find new…
Published on November 28, 2022
Certain biomarkers may predict likelihood of checkpoint inhibitor drugs “backfiring” during melanoma treatment. Duke Cancer Institute researchers have identified a pathway that may explain why this serious side effect occurs in a subset of patients. Using a mouse model of melanoma, the team determined that an NLRP3 inflammasome (HSP70-TLR4) drives premetastatic…
Published on November 18, 2022
Immunotherapy activates the body’s immune system to fight against cancer cells without using chemotherapy or radiotherapy. In addition, it uses the adaptability of the immune system which may help patients benefit from its therapeutic effects experience sustained anti-cancer effects. However, the current diagnostic techniques do not accurately predict the patient’s…
Published on November 16, 2022
Researchers from The University of Texas MD Anderson Cancer Center have developed a nanotechnology platform that can enhance the antitumor effect of immunotherapy in solid tumors by attaching an immune activation molecule to the surface of the tumors. The universal nanobioconjugate platform, termed bispecific tumor-transforming nanoparticles (BiTNs) is the work…
Published on November 2, 2022
A new study by Yale School of Medicine researchers has identified a possible explanation for why some cancers don’t respond to immunotherapy. In an analysis of a Phase II trial investigating the immunotherapy drug pembrolizumab in 24 patients with endometrial cancer, the team found faulty DNA repair in tumors was…
Published on October 12, 2022
Eating a Mediterranean diet, rich in fiber, mono-unsaturated fatty acids and polyphenols, has been associated with improved immunotherapy response rates and progression-free survival in advanced melanoma patients, a new study presented today at UEG Week 2022 has found. Experts anticipate that diet will play a role in the success of…
Published on September 28, 2022
Combination PD-1/CTLA-4 blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAF V600 mutant metastatic melanoma. However, little prospective data existed to guide the choice of initial therapy or sequence in these patients. In a paper in the Journal of Clinical Oncology researchers conducting the DREAMseq…
Published on September 21, 2022
New research from investigators at Tel Aviv University details how tumor cells form temporary cell-in-cell formations to evade immunotherapy. Their findings, published in eLife, may lead to the development of treatments that combine immunotherapy with the inhibition of signaling pathways in tumor cells. “Despite the remarkable successes of cancer immunotherapies,…
Published on September 12, 2022
A striking 63.3% of patients with stage II–IV cutaneous squamous cell carcinoma (CSCC) saw their tumors nearly or completely disappear when treated with immunotherapy before surgery, according to an international, multicenter, Phase II clinical trial led by The University of Texas MD Anderson Cancer Center. The results were presented today at the European Society…
Published on August 31, 2022
A team of researchers at the Biodesign Center for Immunotherapy Vaccines and Virotherapy, at Arizona State University led by Grant McFadden, PhD, and Masmudur Rahman, PhD, has proposed a promising new line of attack for treatment-resistant cancers. Their approach combines oncolytic virotherapy, a technique using cancer-fighting viruses, with existing immunotherapy…
Published on August 10, 2022
In the best of circumstances, only 25% of bladder cancers have a durable response following anti-PD-1/PD-L1 immunotherapy. But investigators at the Cedars-Sinai Cancer Center have identified genetic signatures related to the gene discoidin domain receptor tyrosine kinase 2 (DDR2) that may eventually help predict whether tumors in patients with bladder…